Immune Profiling April 12

Dr Joseph Breen

Chair’s opening remarks

Dr Joseph Breen, Immunoregulation Section Chief, Basic Immunology Branch, Division of Allergy, Immunology and Transplantation, NIAID, NIH, National Institute of Allergy and Infectious Diseases
Dr Roy Baynes

PD-1 Antibodies have the potential to be a broad spectrum antineoplastic treatment both as monotherapy and in combination therapies  

  • PD-1 antibodies are checkpoint inhibitors for the treatment of cancer and act by targeted activation of the immune system
  • Initial activity screening was based upon big data analyses of PDL-1 status and mutational burden of various cancers
  • PD-1 antibody therapy appears to be a broad spectrum anticancer monotherapy and has the potential to be foundational in combination therapy
  • Toxicity profiles of checkpoint blockade and combination checkpoint blockade inform treatment options
  • Precision medicine appears to be key in certain tumour types
Dr Daniel Zimmerman

Addressing the unmet need for therapeutic vaccines for autoimmune conditions with emphasis on arthritis

  • Exploring the current landscape for vaccine therapeutics for autoimmune conditions
  • Sharing updates, mode of mechanisms, and progress regarding development of a vaccine for Rheumatoid arthritis
Dr Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology, CEL-SCI Corporation
Mr Bruno Gomes

Characterization of a novel personalized cancer immunotherapy: A best-in-class adenosine A2A receptor antagonist optimized for high potency in adenosine-rich tumor microenvironment

  • Targeting a new immune-checkpoint in cancer
  • Characterization of the immune mechanism of action a novel immune checkpoint blocker
  • Translational strategy to improve the antitumor efficacy in patients

Networking coffee break

Mr Lei Zheng

Strategies for effective clinical trial design for combinational immunotherapies

Dr Annie De Groot

Immune-Engineering Therapeutic Vaccines: Removing T-reg epitopes in Cancer Immunotherapy, Adding T-reg epitopes for Inducing Tolerance in Autoimmunity

  • Using state-of-the art immunoinformatics tools, EpiVax have uncovered ‘networks’ of T cell epitopes that activate Tregs and down-regulate immune responses
  • These Treg epitopes can be found in tumor associated antigens and in the vaccine antigens of human pathogens; engineering the Treg epitopes out appears to enhance vaccine efficacy
  • Engineering Treg epitopes into tolerance inducing strategies for autoimmunity and allergy is an approach that EpiVax is pursuing as well. This presentation will describe the impact of immune engineering in therapeutic vaccines
last published: 03/Apr/17 13:55 GMT


>> View the full World Vaccine Congress Washington 2017 Agenda including the 7 co-located event streams